首页> 外国专利> Arginine-lysine-aspartic acid-valine-tyrosine polypeptide(s) - induce differentiation of T lymphocytes but not that of B lymphocytes having complement receptor and are used to increase immunity

Arginine-lysine-aspartic acid-valine-tyrosine polypeptide(s) - induce differentiation of T lymphocytes but not that of B lymphocytes having complement receptor and are used to increase immunity

机译:精氨酸-赖氨酸-天冬氨酸-缬氨酸-酪氨酸多肽-诱导T淋巴细胞分化,但不诱导具有补体受体的B淋巴细胞分化,并用于增强免疫力

摘要

Polypeptide derivs. containing the active group of formula (I) have the ability to cause by induction the differentiation T lymphocytes but not that of B lymphocytes having the complement receptor (CR+). The novel polypeptides of formula (II) and their salts are partic. claimed. In the formula R,R1 are terminal gps. joined to the polypeptide which do not influence its biological activity; R is H, 1-7C alkyl, 5-12C aryl, 6-20C alkaryl, 6-20C aralkyl, 1-7C alkanoyl, 1-7C alkenyl, 1-7C alkynyl, Gln, Glu, Gly, Glu-Gln, Gly-Gln, Gly-Glu or Gly-Glu-Gln; R1 is hydroxy-NH2, -NHR, -N(R)2, -OR7, X, Val, Gln, Leu, Tyr, Val-Glyn; Val-Leu, Val-Tyr, Gln-Leu, Gln-Tyr, Gln-Val, Leu-Tyr, Leu-Leu, Tyr-Leu, Val-Gln-Leu, Val-Gln-Leu-Tyr or Val-Glyn-Leu-Tyr-Leu; R7 is 1-7C alkyl, 1-7C alkynyl, 6-20C aryl, 6-20C aralkyl or 6-20C alkaryl and X is halo. Polypeptide intermediate of formula (III) is also novel, (where R1,R2,R3,R4, R5 are protecting groups; R1,R2,R3 and R4 are fixed on the reactive side-chain; R5 is fixed to the alpha-aminoacid and may be removed under conditions which do not remove R1,R2,R3 and R4; the resin is a physically stable, insoluble polymer joined by a covalent bond to the adjacent aminoacid. Typicall R1=tosyl, R2=epsilon-2-chlorobenzyloxycarbonyl; R3=benzyl; R4=0-2,6-dichloro benzyl and R5=amyloxycarbonyl. Typical resins used are cellulose, polymetharcrylate, sulphonated polystyrene and chloromethylated copolymer of styrene and divinylbenzene copolymer of styrene and divinylbenzene. (I) and (II) cause differentiation of bone marrow cells to give T cells, which give rise to the thymus lymphocytes, and are used in the immunitary system of animals and humans. They are used to terat Digeorge syndrome (congenital absence of thymus) and to stimulate immunity in chronic infections e.g. fungal infections due to mycoplasms, tuberculosis, leprosy, chronic and acute viral infections etc. The cpds. are also of interest in auto-immune illness where their are undesered antibodies e.g. generalised ery themateous lupus. They also influence neuromuscular transmission and may be used to treat spasticity.
机译:多肽衍生。含有式(I)活性基团的细胞具有通过诱导引起分化的T淋巴细胞的能力,而不具有诱导具有补体受体(CR +)的B淋巴细胞的分化的能力。式(II)的新型多肽及其盐是特定的。声称。式中,R,R1是末端gps。连接至不影响其生物学活性的多肽; R为H,1-7C烷基,5-12C芳基,6-20C烷芳基,6-20C芳烷基,1-7C烷酰基,1-7C烯基,1-7C炔基,Gln,Glu,Gly,Glu-Gln,Gly -Gln,Gly-Glu或Gly-Glu-Gln; R1为羟基-NH2,-NHR,-N(R)2,-OR7,X,Val,Gln,Leu,Tyr,Val-Glyn; Val-Leu,Val-Tyr,Gln-Leu,Gln-Tyr,Gln-Val,Leu-Tyr,Leu-Leu,Tyr-Leu,Val-Gln-Leu,Val-Gln-Leu-Tyr或Val-Glyn- Leu-Tyr-Leu; R 7是1-7C烷基,1-7C炔基,6-20C芳基,6-20C芳烷基或6-20C烷芳基,X是卤素。式(III)的多肽中间体也是新颖的(其中R 1,R 2,R 3,R 4,R 5是保护基; R 1,R 2,R 3和R 4固定在反应性侧链上; R 5固定在α-氨基酸上R 1 =甲苯磺酰基,R 2 =ε-2-氯苄氧基羰基;并且R 1 =甲苯磺酰基,R 2 =ε-2-氯苄氧基羰基;并且可以在不除去R 1,R 2,R 3和R 4的条件下除去;该树脂是物理稳定的不溶性聚合物,通过共价键与相邻氨基酸结合。 R3 =苄基; R4 = 0-2,6-二氯苄基,R5 =戊氧羰基,典型的树脂是纤维素,聚甲基丙烯酸酯,磺化的聚苯乙烯和苯乙烯的氯甲基化共聚物以及苯乙烯和二乙烯基苯的二乙烯基苯共聚物。骨髓细胞分化为T细胞,产生胸腺淋巴细胞,用于动物和人类的免疫系统,用于治疗Digeorge综合征(先天性胸腺缺失)并刺激慢性感染的免疫力例如由于霉菌引起的真菌感染细菌,结核,麻风病,慢性和急性病毒感染等。对于自身免疫性疾病,如果它们是不需要的抗体,例如全身性红斑狼疮。它们还影响神经肌肉的传递,可用于治疗痉挛。

著录项

  • 公开/公告号SE8204283L

    专利类型

  • 公开/公告日1982-07-12

    原文格式PDF

  • 申请/专利权人 SLOAN KETTERING INST CANCER;

    申请/专利号SE19820004283

  • 发明设计人 GOLDSTEIN G;SCHLESINGER D H;

    申请日1982-07-12

  • 分类号C07C103/52;

  • 国家 SE

  • 入库时间 2022-08-22 13:31:06

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号